Compositions and methods for treating pulmonary hypertension
In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
1. A method of treating pulmonary arterial hypertension, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises a sterile injectable solution comprising a polypeptide comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 32, wherein the polypeptide binds to activin and/or GDF11.
2. The method of claim 1 , wherein the polypeptide is a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 32.
3. The method of claim 1 , wherein the polypeptide is a polypeptide comprising an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 32.
4. The method of claim 1 , wherein the polypeptide is a polypeptide comprising the amino acid sequence of SEQ ID NO: 32.
5. The method of claim 1 , wherein the polypeptide is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 32.
6. The method of claim 1 , wherein the polypeptide is part of a homodimer protein complex.
7. The method of claim 1 , wherein the polypeptide is glycosylated.
8. The method of claim 1 , wherein the polypeptide has a glycosylation pattern obtainable by expression in a Chinese hamster ovary cell.
9. The method of claim 1 , wherein the sterile injectable solution comprises a sterile powder which is reconstituted with an acceptable solution.
10. The method of claim 9 , wherein the acceptable solution is water.
11. The method of claim 1 , wherein the patient has resting pulmonary arterial pressure of at least 25 mmHg.
12. The method of claim 1 , wherein the method decreases pulmonary arterial pressure in the patient.
13. The method of claim 12 , wherein the method reduces the pulmonary arterial pressure by at least 5 mmHg.
14. The method of claim 12 , wherein the method reduces the pulmonary arterial pressure by at least 7 mmHg.
15. The method of claim 1 , wherein the method increases the patient's 6-minute walk distance.
16. The method of claim 15 , wherein the method increases the patient's 6-minute walk distance by at least 40 meters.
17. The method of claim 1 , wherein the method decreases ventricle hypertrophy in the patient.
18. The method of claim 1 , wherein the method decreases smooth muscle hypertrophy in the patient.
19. The method of claim 1 , wherein the method decreases pulmonary arteriole muscularity in the patient.
20. The method of claim 1 , wherein the method decreases pulmonary vascular resistance in the patient.
21. The method of claim 20 , wherein the method decreases pulmonary vascular resistance in the patient by at least 10%.
22. The method of claim 1 , wherein the patient has been treated with one or more vasodilators.
23. The method of claim 1 , wherein the patient has been treated with one or more agents selected from the group consisting of: phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin receptor agonist, and endothelin receptor antagonists.
24. The method of claim 23 , wherein the one or more agents is selected from the group consisting of: bosentan, sildenafil, beraprost, macitentan, selexipag, epoprostenol, treprostinil, iloprost, ambrisentan, and tadalafil.
25. The method of claim 1 , wherein the patient has pulmonary arterial hypertension and has Functional Class II or Class III pulmonary hypertension in accordance with the World Health Organization's functional classification system for pulmonary hypertension.
26. The method of claim 1 , wherein the method delays clinical worsening of pulmonary arterial hypertension.
27. The method of claim 26 , wherein the method delays clinical worsening of pulmonary arterial hypertension in accordance with the World Health Organization's functional classification system for pulmonary hypertension.
28. The method of claim 27 , wherein the method delays clinical worsening of pulmonary hypertension by delaying the progression from Functional Class II to Class III as recognized by the World Health Organization.
29. The method of claim 1 , wherein the method reduces the risk of hospitalization for one or more complications associated with pulmonary arterial hypertension.